Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Byrd

Showing results (11-20 of 681) with videos related to

Pageof 69
Sort By:
Cancer Discovery|July 31, 2015
Mass Cytometry: A High-Throughput Platform to Visualize the Heterogeneity of Acute Myeloid LeukemiaPriscilla Do, John C Byrd
JAMA Oncology|July 17, 2015
IGHV and Interphase Cytogenetics in a Patient With Chronic Lymphocytic LeukemiaJohn C Byrd, Meixiao Long
Best Practice & Research. Clinical Haematology|July 13, 2010
Signalling to drug resistance in CLLErin Hertlein, John C Byrd
Blood|October 19, 2013
IRF4(-/-)Vh11 mice: a novel mouse model of CLLYiming Zhong, John C Byrd
Blood|April 29, 2008
CLL and activated NF-kappaB: living partnershipErin Hertlein, John C Byrd
Cancer Cell|October 12, 2016
A New Role for Lyn in the CLL MicroenvironmentShuai Dong, John C Byrd
Current Opinion in Hematology|June 7, 2006
Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemiaAruna Gowda, John C Byrd
Blood|June 26, 2010
HLA-DR meets ERKErin Hertlein, John C Byrd
Cancer Cell|June 10, 2015
Antagonizing ClpP: A New Power Play in Targeted Therapy for AMLKarilyn Larkin, John C Byrd
Cancer Discovery|March 3, 2019
Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLLShanmugapriya Thangavadivel, John C Byrd
Pageof 69

Showing results (11-20 of 681) with videos related to

Sort By:
Pageof 69
Cancer Discovery|July 31, 2015
Mass Cytometry: A High-Throughput Platform to Visualize the Heterogeneity of Acute Myeloid LeukemiaPriscilla Do, John C Byrd
JAMA Oncology|July 17, 2015
IGHV and Interphase Cytogenetics in a Patient With Chronic Lymphocytic LeukemiaJohn C Byrd, Meixiao Long
Best Practice & Research. Clinical Haematology|July 13, 2010
Signalling to drug resistance in CLLErin Hertlein, John C Byrd
Blood|October 19, 2013
IRF4(-/-)Vh11 mice: a novel mouse model of CLLYiming Zhong, John C Byrd
Blood|April 29, 2008
CLL and activated NF-kappaB: living partnershipErin Hertlein, John C Byrd
Cancer Cell|October 12, 2016
A New Role for Lyn in the CLL MicroenvironmentShuai Dong, John C Byrd
Current Opinion in Hematology|June 7, 2006
Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemiaAruna Gowda, John C Byrd
Blood|June 26, 2010
HLA-DR meets ERKErin Hertlein, John C Byrd
Cancer Cell|June 10, 2015
Antagonizing ClpP: A New Power Play in Targeted Therapy for AMLKarilyn Larkin, John C Byrd
Cancer Discovery|March 3, 2019
Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLLShanmugapriya Thangavadivel, John C Byrd
Pageof 69